claudication

Pentoxifylline (PTX) modulates immunologic activity by stimulating cytokine production. Pentoxifylline is a methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. It also inhibits platelet aggregation and improves blood flow by increasing erythrocyte and leukocyte flexibility.

Buflomedil hydrochloride (Fonzylane), a vasodilator, is used in therapy of claudication or the symptoms of the peripheral arterial disease.

Levocarnitine propionate hydrochloride (ST-261) is used for the treatment of the deterioration of renal function, congestive heart failure, intermittent claudication, and other diseases.

Inositol nicotinate (Mesotal) has the effect of lowering cholesterol and expanding peripheral blood vessels for hypercholesterolemia and atherosclerosis.

Parogrelil is a phosphodiesterase (PDE3 PDE5A) inhibitor potentially for the treatment of intermittent. Parogrelil suppress the asthmatic response in guinea pigs, with both bronchodilating and anti-inflammatory effects. Parogrelil improves reduced walking

Pentoxifylline-d6 is intended for use as an internal standard for the quantification of pentoxifylline by GC- or LC-MS. Pentoxifylline is a hemorrheologic agent. It increases the deformability of washed isolated human erythrocytes when used at a concentration of 100 µM. Pentoxifylline (1, 2, and 3 mM) inhibits ADP-induced platelet aggregation in isolated human whole blood. It inhibits thrombus formation induced by ADP in a hamster cheek pouch model when administered at doses of 5, 10, and 20 mg kg. Formulations containing pentoxifylline have been used in the treatment of intermittent claudication.

MRS5663 (Compound 3a), an A3AR agonist, exhibits an EC50 value of 5.62 nM in β-arrestin2 recruitment assays. This compound demonstrates cytoprotective effects in skeletal muscle ischemia-reperfusion injury/claudication models.